# Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission

> **NCT02373813** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 371 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** etanercept pre-filled syringe subcutaneous injection
- **DRUG:** Oral methotrexate
- **DRUG:** Placebo for etanercept subcutaneous injection
- **DRUG:** Placebo for methotrexate
- **DIETARY_SUPPLEMENT:** Folic acid (non-investigational product)

## Key facts

- **NCT ID:** NCT02373813
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-20
- **Primary completion:** 2019-12-06
- **Final completion:** 2019-12-06
- **Target enrollment:** 371 (ACTUAL)
- **Last updated:** 2023-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02373813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02373813, "Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02373813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*